Journal Mobile Options
Table of Contents
Vol. 5, No. 1, 2005
Issue release date: January–March 2005
Section title: Educational Autumn Meeting: Advances in Cardiovascular Drug Therapy
Heart Drug 2005;5:29–33
(DOI:10.1159/000083384)

Epidemiology and Genetics, Morbidity and Mortality of Lipid-Associated Cardiovascular Disorders

Tonstad S.
Department of Preventive Cardiology, Preventive Medicine Clinic, Ullevål University Hospital, Oslo, Norway

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of Educational Autumn Meeting: Advances in Cardiovascular Drug Therapy

Published online: 2/7/2005
Issue release date: January–March 2005

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED

Abstract

Cardiovascular disease has increased substantially in countries of central and eastern Europe and remains the major cause of premature death in Western populations. Cholesterol plays the major role in the underlying cause of cardiovascular disease, namely atherosclerosis. Epidemiological studies have demonstrated the prospective, strong and dose-dependent relationship between low density lipoprotein cholesterol and cardiovascular disease. In addition, evidence from molecular biology and randomized clinical trials supports the concept that elevated low density lipoprotein cholesterol is both sufficient and necessary for the development of atherosclerosis. Other risk factors than cholesterol greatly enhance the likelihood of symptomatic disease. Monogenic lipid disorders including familial hypercholesterolemia and familial defective apolipoprotein B illustrate the consequences of the dysregulation of cholesterol metabolism.

© 2005 S. Karger AG, Basel


  

Author Contacts

Serena Tonstad, MD, PhD
Department of Preventive Cardiology, Preventive Medicine Clinic
Ullevål University Hospital
NO–0047 Oslo (Norway)
Tel. +47 22 11 79 39, Fax +47 22 11 99 75, E-Mail serena.tonstad@uus.no

  

Article Information

Published online: January 19, 2005
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 0, Number of References : 41

  

Publication Details

Heart Drug (Excellence in Cardiovascular Trials)

Vol. 5, No. 1, Year 2005 (Cover Date: January-March 2005)

Journal Editor: Atar, D. (Oslo)
ISSN: 1422–9528 (print), 1424–0556 (Online)

For additional information: http://www.karger.com/hed


Article / Publication Details

First-Page Preview
Abstract of Educational Autumn Meeting: Advances in Cardiovascular Drug Therapy

Published online: 2/7/2005
Issue release date: January–March 2005

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1422-9528 (Print)
eISSN: 1424-0556 (Online)

For additional information: http://www.karger.com/HED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.